ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (COMMIT) Phase 3 Study: Atezo Monotherapy vs. mFOLFOX6/Bevacizumab/Atezo in the 1L Treatment of dMMR/MSI-H mCRC
By
ASCO 2022 Conference Coverage
FEATURING
Michael Overman
By
ASCO 2022 Conference Coverage
FEATURING
Michael Overman
1,083 views
June 9, 2022
Comments 0
Login to view comments.
Click here to Login
GI